ALK and non-small cell lung carcinoma: Among the eight patients with crizotinib-naive ALK+ NSCLC, median PFS was 34.2 months (95% CI: 7.4–63.9), with PFS rates of 45% (95% CI: 11–75) at 3 years and 30% (95% CI: 4–63) at 5 years.